Mitsubishi UFJ Asset Management Co. Ltd. Buys New Stake in Kenvue Inc. $KVUE

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,028,337 shares of the company’s stock, valued at approximately $96,092,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in Kenvue during the fourth quarter worth about $26,000. MV Capital Management Inc. purchased a new position in Kenvue during the fourth quarter valued at approximately $28,000. CoreCap Advisors LLC raised its position in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after acquiring an additional 591 shares in the last quarter. Finally, Reflection Asset Management acquired a new position in Kenvue in the fourth quarter valued at approximately $32,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on KVUE. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Finally, UBS Group dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $19.27.

Kenvue Stock Up 0.2%

Kenvue stock opened at $18.82 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The stock has a market capitalization of $36.15 billion, a PE ratio of 21.63, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. The business has a 50 day simple moving average of $19.00 and a 200-day simple moving average of $18.16. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.84.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. During the same quarter last year, the business earned $0.29 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.